Physician profile
Mark W Mcclung
NPI 1750380267
$4,995.97
in general payments reported to CMS, 2019-2025
27 companies · $610 in 2025
The $610 reported for 2025 was more than what a typical Plastic and Reconstructive Surgery provider received nationally (typical 2025 total: $445).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $961 · 2020: $1,302 · 2021: $405 · 2022: $656 · 2023: $686 · 2024: $376 · 2025: $610.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,672.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,672.03 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Musculoskeletal Transplant Foundation INC. | $1,134.34 | 2019-2025 | |
| Sientra, INC. | $747.95 | 2019-2022 | |
| Mentor Worldwide LLC | $609.07 | 2019-2025 | Mentor Memorygel Resterilizable Gel Sizer, Artoura Breast Tissue Expander, Mentor Cpx 2 Breast Tissue Expander |
| Allergan, INC. | $478.81 | 2019-2022 | |
| Abbvie INC. | $413.93 | 2023-2025 | |
| Tepha INC | $369.22 | 2019 | |
| Motiva USA, LLC | $232.01 | 2025 | |
| Galderma Laboratories, L.P. | $210.22 | 2020-2025 | Dysport |
| Acelrx Pharmaceuticals, INC. | $99.53 | 2021-2022 | |
| Integra Lifesciences Corporation | $85.45 | 2023-2024 | Integra, Integra Dermal Regeneration Template, Tenoglide |
| Revance Therapeutics, INC. | $71.02 | 2025 | Daxxify |
| Kerecis Limited | $67.75 | 2023-2024 | Kerecis Omega3 Marigen, Kerecis Omega3 Surgiclose, Kerecis Omega3 Graftguide |
| Kowa Pharmaceuticals America, INC. | $66.44 | 2023 | Seglentis |
| Tela Bio, INC. | $57.66 | 2019-2022 | |
| Endo Pharmaceuticals INC. | $54.14 | 2022-2023 | Xiaflex |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Acera Surgical, INC. | $41.08 | 2023-2025 | Restrata Wound Matrix |
| Vertex Pharmaceuticals Incorporated | $37.94 | 2025 | |
| Vertical Pharmaceuticals, LLC | $34.42 | 2023 | Dsuvia |
| Avita Medical Americas, LLC | $33.84 | 2023 | Recell |
| Pacira Pharmaceuticals Incorporated | $28.79 | 2020-2021 | |
| Solta Medical, A Division of Bausch Health US, LLC | $22.37 | 2024 | |
| Endo USA, INC. | $21.08 | 2024 | Xiaflex |
| Organogenesis INC. | $17.96 | 2019 | |
| Rti Surgical, INC | $17.75 | 2024 | |
| Access Pro Medical, LLC | $17.39 | 2025 | Matriderm |
| Arteriocyte Medical Systems, INC. | $13.81 | 2019 | |
| Apyx Medical Corporation | $12.00 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Mcclung listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.